Istodax (romidepsin) / Astellas, BMS - LARVOL DELTA

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response (ASH 2025) - P=N/A | "All patients (100%) had prior exposure to lenalidomide, 97.5% to bortezomib, 85% to carfilzomib, 82% to daratumumab, 77.5% to pomalidomide, and 12.5% BCMA CAR-T therapy...From Oncopanel2 v1, the top drugs by DSS included bortezomib (median DSS 47.7), carfilzomib (median DSS 47.3), panobinostat (median DSS 47), and romidepsin (median DSS 45.4). From Oncopanel2 v2, the top drugs by DSS were marizomib (an investigational PI, with median DSS 46.1), carfilzomib (median DSS 40.2), ixazomib (median DSS 37.2), and oprozomib (an investigational PI, with median DSS 31.6)... The use of a high throughput drug sensitivity assay was feasible among patients with relapsed/refractory MM. In our analysis of drug-specific DSS thresholds for bortezomib and Selinexor, DSS performance varied by agent, highlighting the need for drug-specific threshold optimization. In the patients who received Selinexor, there was a non-significant tendency toward higher DSS scores in responders,..."

Clinical • IO biomarker • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • Plasmacytoma • SDC1

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder (ASH 2025) - "Our 61-year-old patient underwent a living-unrelated renal transplant in 2014 for focal segmental glomerulosclerosis and was maintained on mycophenolate mofetil (MMF) and cyclosporine (CsA)...MMF was discontinued, and he received four weekly doses of rituximab (375 mg/m²), achieving complete remission (CR) and was consolidated with four additional Rituximab doses by Jan 2024...After improvement of liver and kidney function, therapy was escalated to brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone (CHP), given his CD30 expression...After detailed goals-of-care discussions, he and the care team elected to proceed with additional therapy with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), since he already received azacitidine, romidepsin, and BV-CHP...His care underscores the importance of multidisciplinary collaboration, patient-centered decision-making, and longitudinal follow-up. He has been referred to our..."

Clinical • IO biomarker • Post-transplantation • Bone Marrow Transplantation • Chronic Kidney Disease • Epstein-Barr Virus Infections • Febrile Neutropenia • Focal Segmental Glomerulosclerosis • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Peripheral T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • BCL6 • CD21 • CD4 • CD5 • CD7 • ICOS • JAK1 • PD-1 • RHOA • TET2 • TNFRSF8

Survival and response rates of histone deacetylase inhibitors in peripheral T-cell lymphoma: A comprehensive systematic review and meta-analysis of 67 studies. (ASH 2025) - "It has high relapses and unfavorable prognoses with first-line chemotherapy regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone)...Currently, romidepsin, vorinostat, and belinostat have US FDA approval for the treatment of relapsed/refractory PTCL, while chidamide is approved in China but is not approved in the US...HDACi monotherapy in patients with R/R T cell lymphoma, demonstrated an ORR, with chidamide [42%; 95% CI: (0.148, 0.57), p-value = <0.00001, I2=85%] followed by romidepsin [30%; 95% CI: (0.25, 0.35), p-value = <0.00001, I2=35%], abexinostat [28%; 95% CI: (0.19, 0.37), p-value = <0.00001], belinostat [26%; 95% CI: (0.19, 0.33), p-value = <0.00001, I2=0%]... This meta-analysis demonstrates that HDACi has shown overall improved response rates and survival in PTCL patients. However, chidamide has higher response rates than romidepsin in previously treated (UT) patients. In R/R patients, complete remission is higher with romidepsin;..."

Epigenetic controller • Retrospective data • Review • Adult T-Cell Leukemia-Lymphoma • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes (ASH 2025) - "Among acute ATLL pts (n=25), initial therapy included CHOP or CHOEP (40%), hyperCVAD (28%), and Zidovudine + interferon a (AZT+IFN) (20%)...Among lymphomatous subtypes pts (n=24), the majority received CHOP-based regimens initially (79%), followed by salvage with ICE, pralatrexate, or romidepsin...A small number of long-term survivors were observed in acute ATLL with limited tumor burden in the lymph node involvement, associated with early use of AZT+IFN, followed by mogamulizumab, or AlloHCT...Unfortunately, we currently lack highly effective frontline treatment options, which makes consolidative strategies such as transplantation difficult to execute. These findings underscore the urgent need for earlier recognition, subtype-adapted therapy, and suggest the incorporation of antiviral and immune-based strategies to improve ATLL outcomes."

Clinical • Review • Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Endocrine Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy (ASH 2025) - "Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been the standard initial therapy for PTCL; however, clinical outcomes remain suboptimal. The introduction of brentuximab vedotin (BV)-CHP has improved survival in CD30-positive PTCL patients (pts) and has become the standard therapy for this subgroup...Of the 33 pts who subsequently received salvage therapy, 22 received at least one novel agent (e.g., BV, romidepsin, pralatrexate, tucidinostat), and 19 received conventional chemotherapy... PTCL pts who achieved CR after initial therapy demonstrated favorable long-term survival. However, more than half experienced relapse, with no clear plateau in relapse risk. This finding indicates a continued risk of relapse and highlights the need for long-term monitoring."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

NF-κB is a potential therapeutic target for histone deacetylase inhibitor-resistant cutaneous T-cell lymphoma (ASH 2025) - "Histone deacetylase (HDAC) inhibitors, including vorinostat and romidepsin, are used clinically to restore the expression of tumor suppressor genes known to be epigenetically suppressed in CTCL...Finally, we confirmed that HDAC inhibitor-resistant cell lines displayed heightened sensitivity to inhibition of the NF-κB pathway by bortezomib, a proteasome inhibitor that prevents IκB degradation and thereby blocks NF-κB activation, and dimethyl fumarate, an immunomodulatory and anti-inflammatory drug that suppresses NF-κB signaling by reducing the nuclear translocation and phosphorylation of p65. Conclusion : These findings suggest that aberrant NF-κB activation is a central driver of HDAC inhibitor resistance in CTCL. Our results provide a strong rationale for exploring NF-κB inhibition as a therapeutic strategy to restore or enhance the efficacy of HDAC-inhibitor-based therapies, overcome HDAC inhibitor resistance, and improve the outcomes of patients with CTCL."

Epigenetic controller • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • BCL3 • EGR1 • EP300 • GATA3 • HDAC1 • HDAC2 • HDAC3 • HIC1 • RELA • SOX2 • STAT3

The NLP protein is a novel regulator of G2-m Phase of the cell cycle critical for proliferation of human peripheral T-cell lymphomas (ASH 2025) - "Standard regimens such as CHOP or R‑CHOP, along with approved targeted agents(belinostat, romidepsin, pralatrexate), have yielded limited long‑term benefit, with 5‑year survival rates ofonly 20–30%...Homozygous NLP knockout mice are viable butshow ~10% reduction in the body size suggesting that mouse NLP is important but not essential fornormal development.Altogether, our findings identify NLP as a novel regulator of the G2–M phase of the cell cycle with acritical role in the proliferation of malignant T-cells. Given its predicted druggable structure, NLPrepresents a promising candidate for the development of novel targeted PTCL therapies."

Hematological Malignancies • Liver Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Renal Cell Carcinoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • ATF5 • BRCA1 • CHEK2 • EPAS1 • RPL10

BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome (ASH 2025) - "Although most ML-DS patients respond favorably to chemotherapy, outcomes remainpoor in relapsed or refractory cases, which highlights the need for novel therapeutic strategies.We previously demonstrated that dual inhibition of EZH2 and class I histone deacetylases (HDAC) byusing GSK126 and romidepsin synergistically suppressed ML-DS cell viability (Cicek et al., 2022)...Notably, BTK inhibition by Pirtobrutinib, a FDA-approved reversible BTK inhibitor,recapitulated the effects of combination treatment by reducing EZH2 protein level and inducing celldeath of relapsed ML-DS PDX cells via apoptosis. Proteosome inhibition with MG132 in the presence ofPirtobrutinib rescued EZH2 level, indicating that BTK inhibition reduces EZH2 stability via the ubiquitin-proteasome pathway. Furthermore, BTK inhibition suppressed key E2F-related oncogenic targets,including c-MYC, Bcl-xL and MCL-1, while upregulating the cell cycle inhibitor p21.Together, these findings highlight BTK as a novel..."

Acute Myelogenous Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Targeted Protein Degradation • ANXA5 • BCL2L1 • CASP3 • CASP7 • CD34 • GATA1 • MYC • RAD21 • STAG2 • SUZ12

Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis (ASH 2025) - "With theincreasing use of modern systemic therapies (e.g., mogamulizumab, brentuximab vedotin, interferons,photopheresis) over the past decade, we sought to determine whether survival disparities by race persistin the current treatment era.MethodsWe retrospectively reviewed 75 patients with SS treated between January 2015 and June 2025 at MoffittCancer Center...Black patients were more likely toreceive ECP + Pegasys (69.2% vs. 26.8%), romidepsin (61.5% vs. 37.5%), brentuximab (38.5% vs. 14.3%),and combination chemotherapy (61.5% vs. 19.6%) compared to White patients, likely reflecting the moreaggressive nature of their disease.ConclusionOur cohort demonstrated better OS compared to historical studies, likely reflecting the impact of modernsystemic therapies and specialized care at a tertiary center...Black patients in our cohort had a markedly higher prevalence of large-celltransformation, earlier age at diagnosis, and more advanced clinical stage at presentation,..."

Clinical • Cutaneous T-cell Lymphoma • Dermatopathology • Hematological Malignancies • Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium (ASH 2025) - "METHODSThis was a global retrospective cohort study using multiple international cohorts: PETAL (n=1414) andGELL (n=487).1,3,19–21 Two separate independent cohorts validated TTR12 as an OS predictor: anobservational U.S. multicenter cohort (n=138) and the phase 3 randomized trial of romidepsin-CHOPversus CHOP.22 Patients with PTCL-NOS, AITL/TFHL, or ALCL with a CR to 1L were included...TTR12 may be a novel endpoint for clinical trials and may better informtreatment decisions upon progression. Prospective validation and correlation with molecular alterationshas been initiated and is the focus of the PETAL consortium."

Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study (ASH 2025) - P=N/A | "The mostcommon non-cytotoxic therapies were brentuximab vedotin (33 (44.0%)), romidepsin (17 (22.7%)) andimmune checkpoint inhibitors (9 (12.0%)). Fourteen pts (8.3%) underwent palliative interventionsinvolving radiation, steroids, or cyclosporine alone...Outcomes improved for ptstreated with non-cytotoxic agents. Updated data including additional pts and subgroup analyses will bereported at the meeting."

Clinical • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Thyroid hormones enhance the responsiveness of T-cell lymphomas to romidepsin (ASH 2025) - "Hypothyroidism was induced byadministering propylthiouracil (PTU, 0.5 mg/mL in drinking water) for 14 days.We first evaluated the in vitro activity of romidepsin across our panel of TCL cell lines under standardculture conditions. Romidepsin treatment significantly reduced tumor size inboth groups (p < 0.05 vs. vehicle). Notably, the magnitude of tumor growth inhibition was significantlygreater in euthyroid mice compared to hypothyroid counterparts, suggesting that systemic thyroid statusmay play a key role in influencing treatment HDACi response in TCL patients.All together, our findings highlight the importance of thyroid status as a modulator of romidepsin efficacyin patients with TCL and provide a strong basis for further study of TH-regulated epigenetic mechanismsduring HDAC inhibitor treatment, which may contribute to improved therapies and identification of noveltargets."

Endocrine Disorders • Hematological Malignancies • Lymphoma • T Cell Non-Hodgkin Lymphoma • CASP3 • CASP7

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden (ASH 2025) - "Interrogation of 9 neSS patient samples forcancer-associated mutations showed known disease-associated variants in TP53 (n=3), PTEN (n=1),DNMT3A (n=1) and EGR2 (n=1).The median number of systemic treatments for neSS patients was similar to cSS patients (3.5 vs 3).Among the neSS patient cohort, systemic treatments included extracorporeal photopheresis (ECP)(n=16),bexarotene (n=11), interferon (IFN)(n=8), mogamulizumab (n=8), romidepsin (n=4), brentuximab vedotin(BV)(n=3), pembrolizumab (n=3), chemotherapy (n=1), methotrexate (n=1) and clinical trial (n=1). Non-erythrodermic patients with B2 disease (T0-2/B2, neSS) had a significantly betterprognosis compared to classic SS patients with erythroderma (T4/B2, cSS). neSS patients receivedmultiple systemic treatments; however, 4 patients with minimal skin disease were managed withsurveillance or skin-directed therapy alone. Only 3 neSS patients (9.6%) later developed erythroderma.Although neSS patients were more often women..."

Clinical • IO biomarker • Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Pruritus • Sezary Syndrome • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD4 • CD7 • CD8 • DNMT3A • DPP4 • PTEN • TP53

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study. (ASH 2025) - P=N/A | "First-line (1L)systemic regimens were predominantly a) immunomodulatory agents (n=47, 29.3%); including oralretinoid (n=20), extracorporeal photopheresis (n=18), interferon (n=9) followed by b) chemotherapy(n=30, 18.7%) and c) targeted therapies (n=17, 10.6%) including Brentuximab Vedotin (n=6), Romidepsin(n=5), Mogamulizumab (n=3), Vorinostat (n=2) and Pralatrexate (n=1). We present initial data from our prospective LEO-MER cohort, a large US-based multicenter consortia.Our findings demonstrate variability in both diagnostic staging and treatment approaches for MF/SSpatients. The cohort demonstrated worse outcomes with high-risk disease and Black race/ethnicity.These findings warrant further study on the impact of underlying social determinant factors, given thevariability noted in this population."

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD4

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan (ASH 2025) - P | "The median TTNT of each SA after 2nd- or later-linetherapies (mo, 95% CI) was 10.7 (3.9–17.3) for brentuximab vedotin (BV; n = 53, 21%), 5.0 (2.7–7.1) fortucidinostat (n = 36, 14%), 3.9 (2.6–4.8) for romidepsin (n = 80, 31%), 2.1 (0.4–5.2) for darinaparsin (n = 7,3%), 1.8 (1.3–2.5) for pralatrexate (n = 58, 23%), 1.5 (0.6–NE) for forodesine (n = 8, 3%), 1.1 (0.4–2.4) formogamulizumab (n = 22, 9%), 0.7 (0.4–3.5) for denileukin diftitox (n = 5, 2%), and NR (NE–NE) for alectinib(n = 1, 0.4%). In patients with TFHL, romidepsin (44%) and tucidinostat (18%) yielded median TTNTs (mo,95% CI) of 4.0 (2.6–8.7) and 5.5 (1.9–7.8), respectively... To the best of our knowledge, this study reports the most recent treatment patterns andprognoses for patients with R/R MTNKL. No standard of care has been established, as diverse treatmentpatterns have been observed. SAs resulted in similar survival outcomes to CCs in 2nd-line therapy,despite distinctive clinical Background of the groups."

Clinical • Observational data • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Extranodal Natural Killer/T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas (ASH 2025) - P1/2 | "In this context, the PTCL-13 study was designed toevaluate the addition of Romidepsin to anthracycline-based chemotherapy (Ro-CHOEP) followed byautologous stem cell transplantation (SCT) (NCT02223208)...Collectively, our findings underscore the potential of integrative molecularprofiling as a tool to guide risk stratification and provide biological insights beyond conventionalhistological sub-classification. Ongoing studies integrating bulk RNA sequencing and whole genomesequencing data into this model will be presented, allowing us to further refine molecularcharacterization of PTCLs."

Biomarker • Follicular Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • CARD11 • CD14 • CD163 • CD20 • CD22 • CD276 • CD33 • DNMT3A • IKZF2 • MS4A1 • NOTCH1 • PD-L2 • RHOA • TCF7 • TET2 • TP63

Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders (ASH 2025) - "Patients were grouped by treatment:those offered cytotoxic chemotherapy, romidepsin, pralatrexate, or alemtuzumab were assigned togroup 1, and all others were assigned to group 0.Sequencing was performed on skin biopsies using whole exome DNA, whole transcriptome RNA, andusing a targeted gene panel.Results79 patients with skin biopsies showing CD30+ T cell LPD were included. Increased proliferativesignaling and MYC-driven transcriptional programs are associated with high risk disease, and an increasein resting dendritic cells in lesional skin is associated with low risk disease. Future studies are needed forvalidation of these findings for prognostication."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • B2M • BCOR • BIRC3 • CUL1 • EPHB1 • ERO1A • GNAS • IL2RA • JAK3 • KDR • KIF23 • NBN • NCOR2 • PRDM1 • PRKDC • SSBP1 • TET2 • TGFBR2 • TNFRSF8

Mechanism of acquired resistance to histone deacetylase inhibitor, romidepsin, in myeloid leukemia associated with down syndrome (ASH 2025) - "In our previous work, we showed that EZH2 inhibitor GSK126, and class I histone deacetylase(HDAC) inhibitor romidepsin, synergistically induced ML-DS cell death (Cicek et al., 2022). RNA-Seq revealed a 4.5-fold increase in ITGB3 TPM, which was confirmed by 8-fold elevated integrin b3 (CD61) protein expression in CMY-R cells. RNA-Seq indicated an upregulation ofCD34 expression in resistant cells, and we confirmed increased CD34, CD44 and CD117 expression inCMY-R cells by flow cytometry, which indicates a shift toward stem-like, adhesion-dependent phenotype.Our findings suggest that resistance to romidepsin in ML-DS involves upregulation of inflammatorysignaling, increased ECM and cell adhesion signaling, and elevated expression of stem cell markers.Targeting inflammatory signaling and/or integrin-mediated adhesion signaling may enhance the efficacyof HDACi and overcome drug resistance in ML-DS and other leukemias."

Epigenetic controller • Preclinical • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CD34 • CD44 • ITGB3 • KIT • STAT1

Humanized PDX models reveal Lymphoma–Host interactions and enhanced T-cell therapies via epigenetic modulation (ASH 2025) - "To explore this complex ecosystem,we analyzed DLBCL biopsies from patients receiving chemotherapy (R-CHOP) or immunotherapy(chimeric antigen receptor CAR T cells) using integrated omics and functional assays, together with fullyhumanized mouse models (HuMice). We analyzed 68 DLBCL cases (48 post R-CHOP and 20 post CAR T-cell–treated) and 48 matchedpatient-derived xenografts (PDX) by bulk RNA-seq, single-cell RNA/TCR-seq, and WES/CAPP-seq...However, splenic T-cells from IR-DLBCL-HuPDX exhibited strong proliferation, clonal expansion, and cytotoxicity against matched tumors.To enhance responses in ID-DLBCL-HuPDX, we performed dose-response screens of single- and dual-drug combinations using clinical phase compounds shown to improve immune responses (e.g.,valemetostat, DNMT1i, GSK-3685032, azacytidine, belinostat, romidepsin, and lenalidomide) and identifysynergistic associations (Vale+GSK, Vale+ Lena: Synergy Score >20)... Epigenetic therapies reprogram the..."

IO biomarker • IO Companion diagnostic • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD34 • CD8 • DNMT1 • IFNG • TNFA

The Pharmacological Atlas of Meningiomas (SNO 2025) - "The top five drugs with the lowest IC50 values were romidepsin, dactinomycin, carfilzomib, plicamycin, and omacetaxine, with median values of 10, 31, 145, 303, and 400 nM, respectively. Considering the ratio of peak serum concentration (Cmax) to IC50 as a potential predictor of treatment efficacy (>1), the HDAC inhibitors belinostat (74.5), romidepsin (69.7), along with the proteasome inhibitor carfilzomib (34.6), and the anthracyclines epirubicin (2.6), and doxorubicin (1.8), and the PI3K inhibitor idelalisib (1.6) are the most promising drug candidates for further evaluation. This study offers the first comprehensive insight into the pharmacological landscape of meningiomas, providing a crucial foundation for future clinical trials aimed at developing systemic treatments for aggressive meningiomas."

Brain Cancer • Meningioma • Solid Tumor

HDAC INHIBITORS AS POTENTIAL SFT THERAPIES (CTOS 2025) - "In conclusion, HDACi Romidepsin shows selective efficacy in Nab2-Stat6 expressing cells, potentially due to metabolic reprogramming. These findings highlight HDAC inhibition as a promising therapeutic strategy for SFT. Building on these findings, the ongoing work explores mechanisms of action and synergistic FDA-approved drug combinations, focused on proteasome inhibitors."

Oncology • EGR1 • NAB2 • STAT6

Clinical revival of romidepsin with nanoparticles. (PubMed, Blood) - No abstract available

Journal

Romidepsin Identified as Candidate for Treating Relapsed Neuroblastoma (Inside Precision Medicine) - "The research, published in Science Advances, shows that an approved drug for lymphoma called romidepsin can induce cell death in neuroblastoma through pathways that remain active even when standard chemotherapy drugs lose effectiveness...The data showed that romidepsin, when combined with chemotherapy, reduced tumor growth and extended survival compared with standard treatment alone. An important finding was that including romidepsin in a combined treatment required lower doses of chemotherapy to be effective, which could alleviate the long-term side effects of high-dose chemotherapy....In addition to their search for a drug that could be repurposed for treating neuroblastoma, the researchers also looked to find out why some chemotherapy combinations fail to produce strong responses."

Preclinical • Neuroblastoma

The Pharmacological Atlas of Meningiomas (WFNOS 2025) - "The top five drugs with the lowest IC50 values were romidepsin, dactinomycin, carfilzomib, plicamycin, and omacetaxine, with median values of 10, 31, 145, 303, and 400 nM, respectively. Considering the ratio of peak serum concentration (Cmax) to IC50 as a potential predictor of treatment efficacy (>1), the HDAC inhibitors belinostat (74.5), romidepsin (69.7), along with the proteasome inhibitor carfilzomib (34.6), and the anthracyclines epirubicin (2.6), and doxorubicin (1.8), and the PI3K inhibitor idelalisib (1.6) are the most promising drug candidates for further evaluation. This study offers the first comprehensive insight into the pharmacological landscape of meningiomas, providing a crucial foundation for future clinical trials aimed at developing systemic treatments for aggressive meningiomas."

Brain Cancer • Meningioma • Solid Tumor

An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL (ASH 2024) - P1/2 | "Through single-cell analysis, we were able to simultaneously detect various biomarkers in neoplastic cells and the immune microenvironment while considering spatial relationships. Further integration of biomarker for treatment response and resistance mechanisms will be presented at the annual meeting."

Genomic analysis • IO biomarker • Omic analysis • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD20 • CD4 • CD68 • CD8 • DNMT3A • IDH2 • PD-1 • PLCG1 • RHOA • STAT3 • TET2